The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), a Manufacturing USA institute, is pleased to announce funding for 14 new projects in technology, workforce development, and in their Global Health Fund initiative, resulting from the Institute’s Project Call 3.1, and with a total value of approximately $10M.
“New manufacturing technologies are crucial to bringing safe, life-saving treatments to patients faster and, now more than ever, the biopharma industry, is seeing an increased demand for skilled talent,” states Kelvin H. Lee, Institute Director, adding, “NIMBL is strategically positioned to bring forth collaborative innovation to meet the growing needs of the industry through our industry, academic and government stakeholders.”
As a result of these new Project Call 3.1 projects, NIIMBL is bolstering their technology portfolio to include critical areas such as process analytical technologies for contaminant detection, cell therapy manufacturing processes, single-use components for continuous manufacturing, and data analytics applications in biomanufacturing. The workforce projects selected offer a range of new skills for incumbent workers in the field of cell therapy, tap into the skills and dedication of military members to provide new career avenues, and pilot industry-academia hybrid training to provide relevant and valued skills especially with today’s virtual needs.